Abstract: A contact lens having antioxidant properties is described as well as methods of manufacturing the same. The contact lens can be present in a sealed contact lens package. The seal contact lens package can include at least a) a plastic base member having a cavity; b) a contact lens packaging solution in the cavity; c) a sterile, unworn contact lens immersed in the contact lens packaging solution in the cavity; and d) a cover that forms a liquid-tight seal with the plastic base member. As an example, the unworn contact lens is a silicone hydrogel contact lens having present therein vitamin E. The vitamin E is non-releasable from the unworn contact lens and the contact lens packaging solution has less than 1 ppm of vitamin E present. The vitamin E is trapped, embedded, absorbed, or non-covalently attached in the unworn contact lens.

Abstract: The invention is directed to topical drug vehicle platform compositions for ophthalmological and dermatological use. These compositions comprise a means to sequester tears and an ophthalmological drug. The invention is further directed to methods of treating a spectrum of ocular surface disease epitheliopathies including but not limited to dry eye in a human or mammal. The invention is further directed to contact lenses, punctum plugs, pellets or any other device used to deliver drugs to the surface of the eye, coated or infused with compositions of the invention.

Abstract: Engineered human tissue seed constructs are provided that are suitable for implantation in subjects. Methods of making and using the engineered tissue seed constructs are provided.

Abstract: The technology relates to a prophylactic bandage contact lens that prevents microbial infections in an eye as well as treats infection by dispensing antimicrobial medication at controlled rates. In one embodiment, the invention provides a bandage with nanostructures, and provides a continuous treatment over 10 days and shields the eye from the environment, significantly diminishing the risk of infection while allowing damaged tissues to heal.

Abstract: The present invention relates to copolymers made from a polymerization mixture comprising (a) one or more polymerizable monomers, which monomers are characterized as having at least one vinylic group and not containing an amino acid residue, (b) one or more not-functionalized side chain-linked amino acids, (c) one or more functionalized side chain-linked amino acids, (d) a free radical initiator and, optionally, (e) a chain-transfer-agent. It also relates to block copolymers comprising the same monomers. The invention also encompasses silicone hydrogel contact lenses coated with or comprising the latter copolymers and block copolymers as well methods for introducing the copolymers and block copolymers into silicone hydrogel contact lenses.

Abstract: The invention relates to electronic contact lens systems, methods for fabrication thereof, and uses thereof for treatment of ophthalmic diseases and conditions, for example, meibomian gland dysfunction.

Abstract: An ophthalmic device includes an optic including an optic axis and a haptic structure coupled with the optic. The haptic structure includes an inner ring comprising a plurality of hinges such that portions of the inner ring reside at different radii from the optic axis. The haptic structure further includes a first loop extending from the inner ring and having two points of connection to the inner ring and a second loop extending from the inner ring and having two points of connection to the inner ring. The second loop is oriented opposite the first loop.

Abstract: A therapeutic system comprises an ocular insert placed on a region outside an optical zone of an eye. The ocular insert comprises two structures: a first skeletal structure and a second cushioning structure. The first structure functions as a skeletal frame which maintains positioning of the implant along the anterior portion of the eye and provides support to the second, cushioning structure. This first structure maintains the attachment of the therapeutic system to the anterior portion of the eye for at least thirty days. In some embodiments the first structure remains a constant size and shape, e.g. a ring shape, a ring with haptics, or a curvilinear ring that is confined to and restrainingly engages the inferior and superior conjunctival fornices so as to retain the implant within the tear fluid and/or against the tissues of the eye.

Abstract: A device comprises a surface that is a hydrogel having a targeted mesh size that permits a low-speed friction coefficient near or lower that that typically reported for cartilage of 0.01 to 0.02, a transition. The device can be a contact lens to sit on the cornea where, during a blink, eyelid slides past the eye surface at about 100 mm s?1. The hydrodynamic lubrication of the hydrogel of the device separates the contact lens surface from the surfaces of the tarsal conjunctiva and marginal conjunctiva of the eyelid. Other devices that can comprise the hydrogel of a targeted mesh size are those that can contact cartilage of articulating joints.

Abstract: The present disclosure provides apolipoprotein (apo) mimetics useful for the treatment of age-related macular degeneration (AMD) and other eye disorders. The apo mimetics can be peptides/polypeptides that mimic, e.g., the lipid-clearing action of apolipoproteins such as apoA-I and apoE. The apo mimetics can exert other beneficial effects, such as reduction of inflammation, oxidative stress and neovascularization. The apo mimetics can be used to treat any stages (including the early, intermediate and advance stages) of AMD, and any phenotypes of AMD, including geographic atrophy (GA) (including non-central GA and central GA) and neovascularization (NV) (including types 1, 2 and 3 NV). The apo mimetics can be used alone or in conjunction with other therapeutic agents, such as a complement inhibitor and/or an anti-angiogenic agent, to treat AMD, including atrophic AMD and neovascular AMD, and other eye disorders.

Abstract: The invention relates to a soft hydrogel contact lens, especially a silicone hydrogel contact lens, which has a capability of delivering a hydrophobic comfort agent into the eye of a wearer. The hydrophobic comfort agent includes without limitation a monoglyceride, a diglyceride, a triglyceride, a glycolipid, a glyceroglycolipid, a sphingolipid, a sphingo-glycolipid, a phospholipid, a fatty acid, a fatty alcohol, a hydrocarbon having a C12-C28 chain in length, a mineral oil, a silicone oil, or a mixture thereof. It can be released from the soft hydrogel contact lens into the eye of a wearer when being worn so as to strengthen and stabilize the tear film lipid layer and alleviate the dryness of the eye.

Abstract: A method for treating and preventing diseases associated with neutrophil infiltration, particularly ocular diseases, is provided, which method comprises administering to a subject in need thereof an effective amount of ceramide or a derivative thereof. Also provided is a composition for treating diseases associated with neutrophil infiltration, the composition comprising ceramide or a derivative thereof.

Abstract: A therapeutic system comprises an ocular insert placed on a region outside an optical zone of an eye. The ocular insert comprises two structures: a first skeletal structure and a second cushioning structure. The first structure functions as a skeletal frame which maintains positioning of the implant along the anterior portion of the eye and provides support to the second, cushioning structure. This first structure maintains the attachment of the therapeutic system to the anterior portion of the eye for at least thirty days. In some embodiments the first structure remains a constant size and shape, e.g. a ring shape, a ring with haptics, or a curvilinear ring that is confined to and restrainingly engages the inferior and superior conjunctival fornices so as to retain the implant within the tear fluid and/or against the tissues of the eye.

Abstract: A contact lens for the human eye includes a matrix and polymer nanocapsules mixed in the matrix. The polymer nanocapsule is calculated to decompose by chemical reaction and thereby release oxygen, to prevent corneal hypoxia. A material for making a contact lens is also provided.

Abstract: Methods for the prevention and treatment of ocular disorders, in particular glaucoma, through blocking the toxic effects of ?-amyloid (A?) derivatives, pharmaceutical compositions for effecting such prevention and interval treatment thereof.

Abstract: This application discloses ophthalmic formulations and methods for treating inflammatory disease and conditions of the ocular surface with one or more C—C chemokine receptor type 7 (CCR7) antagonists. The compositions may be formulated for subconjunctival or topical administration to the eye and are effective in the treatment of inflammatory disease and conditions of the ocular surface.

Abstract: An ophthalmic formulation that includes nanoparticles. Each nanoparticle includes a shell which encapsulates sulfated non-anticoagulant heparin (SNACH), with or without hydrophobic anti-angiogenesis Tyrosine Kinase inhibitors. The SNACH is ionically or covalently bonded to the shell. The shell includes a polymer selected from the group consisting of poly (lactic-co-glycolic acid) (PLGA), chitosan, chitosan-alginate, and NIPAAM-APMAH-AA, wherein NIPAAM is N-isopropyl acrylamide, APMAH is N-3-aminopropylmethacrylamide hydrochloride, and AA is acrylic acid. A method for treating an eye disease of a subject includes: administering to an eye of the subject a therapeutically effective amount of the ophthalmic formulation for treating the eye disease. The eye disease involves an ocular angiogenesis-mediated disorder.

Abstract: Peptide compounds based on the CAP37 protein are disclosed, along with methods for treating various infections, wounds, and conditions, and methods of promoting healing and acceptance of grafts, using compositions containing these peptide compounds.

Abstract: Peptide compounds based on the CAP37 protein are disclosed, along with methods for treating various infections, wounds, and conditions, and methods of promoting healing and acceptance of grafts, using compositions containing these peptides.

Abstract: A drug delivery system is disclosed. The drug delivery system includes a recognitive polymeric hydrogel through which a drug is delivered by contacting biological tissue. The recognitive polymeric hydrogel is formed by using a bio-template, which is a drug or is structurally similar to the drug, functionalized monomers, preferably having complexing sites, and cross-linking monomers, which are copolymerized using a suitable initiator. The complexing sites of the recognitive polymeric hydrogel that is formed preferably mimics receptor sites of a target biological tissue, biological recognition, or biological mechanism of action. The system in accordance with an embodiment of the invention is a contact lens for delivering a drug through contact with an eye.

Abstract: Disclosed herein are several apoplipoprotein E (ApoE) polypeptides, and nucleic acids encoding these polypeptides, that can be used to treat or prevent a hepatitis infection in a subject, such as a hepatitis C virus infection. These ApoE polypeptides can inhibit the entry of hepatitis C virus into cells, and inhibit viral replication. Nucleic acids encoding these polypeptides are also disclosed, as well as methods for their preparation.

Abstract: A system and method for delivering a payload to ocular tissue includes a solution of light-degradable nanoparticles encapsulating the payload. The solution may be introduced to the ocular tissue by way of injection or through a contact lens into which the solution is embedded. A light source delivers a beam of light to the ocular tissue at the location where the solution was introduced to initiate breakdown of the particles, releasing the payload. The light source may be a laser, LED, LCD or arc lamp emitting in the ultraviolet light range.

Abstract: The present invention is directed to an ophthalmic lens integrally formed with a hydrogel, the hydrogel including a copolymer obtained from a composition containing (A) an ionic compound including a cation having a polymerizable functional group, and a fluorine-containing anion (hereinafter, referred to as (A) ionic compound), and (B) a hydrophilic compound having a polymerizable functional group.

Abstract: The present invention provides synthetic antibacterial peptides comprising a sequence at least 80% identical to a sequence shown in SEQ ID NO: 2 or the diastereomer thereof with a sequence shown in SEQ ID NO: 3 or pharmaceutical compositions thereof. Also provided are methods for reducing the severity of microbe-induced inflammation and for stimulating wound healing via the synthetic antibacterial peptides. Further provided is a device having a surface with a coating comprising the synthetic antibacterial peptides.

Abstract: The invention provides compositions and methods utilizing low concentrations of selective ?-2 adrenergic receptor agonists, preferably, brimonidine. The invention provides contact lens solutions and methods of using these solutions for pre-soaking contact lenses to achieve reduction of redness and/or increase in whitening of eyes. The invention also provides compositions including a selective ?-2 adrenergic receptor agonist in a combination with an ocular medical device, including but not limited to a bandage lens. The invention also provides combination compositions including a selective ?-2 adrenergic receptor agonist and another active agent for the treatment of an ocular condition, including but not limited to glaucoma and/or a condition associated with eye redness.

Abstract: The invention relates to acrylic hydrogels with pendant cyclodextrins, the preparation and application thereof as release systems and components of contact lenses. The method for obtaining acrylic hydrogels with pendant cyclodextrins is characterized in that the hydrogels are formed by a polymer lattice obtained by polymerization of mono- and bifunctional acrylic or methacrylic monomers and monomers having glycidyl groups in their structure, to which cyclodextrin units are covalently bound once formed; and the use and applications of the compositions in the preparation of contact lenses with the capacity for incorporating drugs, active substances or demulcents useful in the treatment of pathological or physiological conditions, in the production of topical, transdermal or transmucosal release systems for medicinal products or active substances, and in the preparation of cosmetics.

Abstract: The invention relates to a device (1) for the transplantation of cells (3) in suspension comprising a support with at least one micro-cavity (2) containing or able to contain said suspension in direct contact with the object on which the cells are to be transplanted. The device is intended for application to human tissue or human or animal body, such as the eye, the gingiva, skin, a wound or a burn.

Abstract: A minimally invasive controlled drug delivery system for delivering a particular drug or drugs to a particular location of the eye, the system including a porous film template having pores configured and dimensioned to at least partially receive at least one drug therein, and wherein the template is dimensioned to be delivered into or onto the eye.

Abstract: The present invention provides an ophthalmic device, and method of use thereof, for an individual wearing an ophthalmic lens to increase ocular surface boundary lubrication. The invention device comprises an ophthalmic lens and a sacrificial mechanism disposed on the ophthalmic lens, wherein the sacrificial mechanism comprises a plurality of surface bound receptors, such as PRG4, hyaluronic acid, and DNA aptamers, that reversibly bound to a lubricating composition comprising a gel forming agent, a surfactant, or a combination thereof, effectively inhibiting or preventing protein and lipid adsorption on the surface of the lens, and mitigate shear stress and reduce the friction between the lens and the ocular surface of the individual in need.

Abstract: A scleral lens is provided with a sodium channel blocker or a sodium channel modulator disposed in the pre-corneal tear film between the scleral lens and the cornea. This system can be used to deliver sodium channel blockers or a sodium channel modulators not currently used because of poor bioavailability. Methods of using this sodium channel blocker delivery system or a sodium channel modulator delivery system are also disclosed.

Abstract: Disclosed is a sustainedly drug-releasing hydrogel contact lens which can sustainedly release an anionic medicament such as an allergy-treating agent in a mildly irritating and effective manner while achieving vision correction. Specifically disclosed is a hydrogel comprising ionic monomers composed of at least a cationic monomer and an anionic monomer, wherein the component ratio of the ionic monomers is 5 to 20 mol % inclusive relative to the total amount of monomers that constitute the gel, and the content of the anionic monomer is 15 to 25 mol % inclusive relative to the content of the cationic monomer.

Abstract: Stated is a charging-current regulating device for charging an energy storage device for a field device, and for regulating a charging current for the energy storage device, wherein regulating the charging current for the energy storage device takes place in such a manner that a limiting value relating to an input current of the field device is not exceeded. Regulating the charging current may take place in such a manner that energy storage takes place as quickly as possible and without overloading an input protection circuit of the field device.

Abstract: Contact lenses are described that include particles of polymer fiber mat incorporated into a polymer lens wherein the polymer fiber mat is formed by electrospinning a prepolymer solution. Methods for making the contact lenses with improved oxygen permeability are also described. Methods for making the contact lens with optional therapeutic drug delivery and refractive correction are also described.

Abstract: Ophthalmic conditions such as presbyopia, myopia, and astigmatism can be corrected by the use of a molding contact lens in combination with a pharmaceutical composition suitable for delivery to the eye. The molding contact lenses are preferably commercially available and are not specifically designed for orthokeratology. The agents in the pharmaceutical compositions such as hyaluronase allow the cornea of the eye to be molded in order to correct the refractive error of the eye. The contact lenses and the pharmaceutical composition induce a change in the radius of curvature of the anterior surface of the cornea, thereby correcting the refractive error of the eye. One advantage of the inventive technique is that the patient with his or her own individual visual needs guides the treatment until the patient near and far visual needs are met.

Abstract: The present invention relates to polymeric compositions useful in the manufacture of biocompatible medical devices. More particularly, the present invention relates to certain cationic random copolymers capable of polymerization to form polymeric compositions having desirable physical characteristics useful in the manufacture of ophthalmic devices. Such properties include the ability to extract the polymerized medical devices with water. This avoids the use of organic solvents as is typical in the art. The polymer compositions comprise polymerized siloxane prepolymer containing pendant cationic and polymerizable groups.

Abstract: The instant invention pertains to a method for producing contact lenses with improved oxidative stability of Carotenoids in the contact lens. The method of the invention involves adding a vitamin E material into a contact lens in an amount sufficient to reduce oxidative degradation of Carotenoids in the lens by at least about 30% in comparison with an identical contact lens without the vitamin E material.

Abstract: The invention comprises a transdermal dosage form comprising an active agent component comprising an active agent and an adverse agent component comprising an adverse agent, wherein the active agent component defines at least one channel extending substantially there through.

Abstract: The present invention relates to water soluble quaternized chitosan derivatives which form hydrogel matrix with broad antimicrobial properties for the protection and coating of medical device. Hydrogel is attractive as an antimicrobial coating since its hydrophilicity intrinsically prevents the reversible nonspecific attachment of microbes. In order to achieve hydrogel formation, quaternized chitosan can be grafted with polymerizable groups, especially photocrosslinkable groups, such as methacrylates, PEG derivatives and be converted into hydrogels through a thermal or UV polymerization process. Hydrogels are hydrated cross-linked polymeric systems that contain water in an equilibrium state forming cushion water shield. The present invention is widely used in many medical devices.

Abstract: Disclosed are uses of rare earth element selected from the group consisting of cerium (Ce), praseodymium (Pr), promethium (Pm), europium (Eu), terbium (Tb), dysprosium (Dy), holmium (Ho), erbium (Er), thulium (Tm), ytterbium (Yb), scandium (Sc), yttrium (Y), lanthanum (La), neodymium (Nd), samarium (Sm), gadolinium (Gd), lutetium (Lu) and mixtures thereof, or a salt or an oxide thereof for preventing hair loss, promoting hair regrowth and hair growth, removing and preventing dandruff, or promoting black hair formation.

Abstract: The present invention relates to water soluble quaternized chitosan derivatives which form hydrogel matrix with broad antimicrobial properties for the protection and coating of medical device. Hydrogel is attractive as an antimicrobial coating since its hydrophilicity intrinsically prevents the reversible nonspecific attachment of microbes. In order to achieve hydrogel formation, quaternized chitosan can be grafted with polymerizable groups, especially photocrosslinkable groups, such as methacrylates, PEG derivatives and be converted into hydrogels through a thermal or UV polymerization process. Hydrogels are hydrated cross-linked polymeric systems that contain water in an equilibrium state forming cushion water shield. The present invention is widely used in many medical devices.

Abstract: The present invention relates to topical ophthalmic compositions for treating or preventing epithelial lesions or ophthalmic disorders, including dry eye or keratoconjunctivitis sicca.

Abstract: Formulations of cross-linkable polymers, capable of forming non-toxic and biocompatible hydrogels in situ, containing at least one of doxycycline or minocycline. Methods of using the hydrogels for treating the skin or ocular tissues of mammals exposed to vesicant compounds such as sulfur mustard (SM), nitrogen mustard (NM) or half mustard (2-chloroethyl ethyl sulfide (CEES)) are also disclosed.

Abstract: Ophthalmic conditions such as presbyopia, myopia, and astigmatism can be corrected by the use of a molding contact lens in combination with a pharmaceutical composition suitable for delivery to the eye. The molding contact lenses are preferably commercially available and are not specifically designed for orthokeratology. The agents in the pharmaceutical compositions such as hyaluronase allow the cornea of the eye to be molded in order to correct the refractive error of the eye. The contact lenses and the pharmaceutical composition induce a change in the radius of curvature of the anterior surface of the cornea, thereby correcting the refractive error of the eye. One advantage of the inventive technique is that the patient with his or her own individual visual needs guides the treatment until the patient near and far visual needs are met.

Abstract: A scleral lens is provided with a sodium channel blocker or a sodium channel modulator disposed in the pre-corneal tear film between the scleral lens and the cornea. This system can be used to deliver sodium channel blockers or a sodium channel modulators not currently used because of poor bioavailability. Methods of using this sodium channel blocker delivery system or a sodium channel modulator delivery system are also disclosed.

Abstract: The invention relates to a process for producing biomedical articles, in particular, silicone hydrogel contact lenses having durable hydrophilic chitosan coating. The chitosan coating is covalently attached to the medical device by performing a crosslinking reaction between chitosan and the carboxylic groups on the surface of a medical device directly in a sealed package during autoclave. The coated biomedical articles obtainable by the process of the invention have desirable characteristics regarding adherence to the substrate, durability, hydrophilicity, wettability, biocompatibility and permeability and are thus especially useful in the field of ophthalmic devices.

Abstract: The present invention provides a method for preparing a medical device, preferably a contact lens, having an antimicrobial metal-containing LbL coating on a medical device, wherein the antimicrobial metal-containing LbL coating comprises at least one layer of a negatively charged polyionic material having —COOAg groups and/or silver nanoparticles formed by reducing Ag+ ions associated with the —COO? groups of the negatively charged polyionic material. In addition, the present invention provides a medical device prepared according to a method of the invention.

Abstract: The present invention discloses a drug-carrying contact lens and a method for fabricating the same. The drug-carrying contact lens comprises a contact lens containing at least one amphiphatic hybrid nanocarrier carrying drug molecules. According to the heat or light sensitivity of the drug molecule, the present invention respectively fabricates an encapsulation-type drug-carrying contact lens and a drug-soaking type drug-carrying contact lens. The present invention uses a highly-biocompatible amphiphatic hybrid nanocarriers having superior drug encapsulation capability to wrap the drug molecules. Thereby, the drug molecules are uniformly distributed in the contact lens and can be gradually and locally released to the eye of the user wearing the contact lens. Therefore, the present invention can prevent or cure ocular diseases with the loss and side effects of the drug being reduced.

Abstract: Ophthalmically compatible contact lenses include lens bodies configured for placement on a cornea of an animal or human eye. The lens bodies are made of a hydrophilic silicon-containing polymeric material. The lens bodies have oxygen permeabilities, water content, surface wettabilities, flexibilities, and/or designs to be worn by a lens wearer even during sleep. The present lenses can be worn on a daily basis, including overnight, or can be worn for several days, such as about thirty days, without requiring removal or cleaning.

Abstract: Provided are compositions containing engineered particles, and methods of making such engineered particles. Polymeric articles, such as contact lenses, prepared from such compositions are also provided. Such engineered particles are dispersible in hydrophilic systems such as monomer systems for preparation of contact lenses. Each of the engineered particles comprises a hydrophobic core and a hydrophilic shell. The hydrophobic core comprises a silicone-based polymer that can have multiple cross-links and/or polymer-polymer entanglement, and the hydrophilic shell is formed from a reactive stabilizer. A residue of the reactive stabilizer or a hydrophilic segment of the reactive stabilizer can form the shell. The particles have an average particle size of less than about 500 nm.

Abstract: This invention provides novel active agents (e.g. peptides, small organic molecules, amino acid pairs, etc.) peptides that ameliorate one or more symptoms of eye disease and/or other pathologies characterized by an inflammatory response. In certain embodiment, the peptides resemble a G* amphipathic helix of apolipoprotein J. The agents are highly stable and readily administered via an oral route or via intraocular injection.